(BBNX) Beta Bionics, Common Stock - Ratings and Ratios
Bionic Pancreas, Patch Pump, Bihormonal iLet
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 73.5% |
| Value at Risk 5%th | 104% |
| Relative Tail Risk | -13.65% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.75 |
| Alpha | 3.58 |
| CAGR/Max DD | 0.66 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.584 |
| Beta | 1.831 |
| Beta Downside | 2.197 |
| Drawdowns 3y | |
|---|---|
| Max DD | 59.22% |
| Mean DD | 25.53% |
| Median DD | 24.15% |
Description: BBNX Beta Bionics, Common Stock November 17, 2025
Beta Bionics, Inc. (NASDAQ: BBNX) is a commercial-stage medical-device firm focused on automated insulin-delivery technologies for people who require insulin. Its flagship product, the iLet Bionic Pancreas, is cleared for use in adults and children six years and older with type 1 diabetes, while pipeline programs include a skin-adhesive Patch Pump, a bihormonal iLet that co-delivers insulin and glucagon, and an iLet variant aimed at insulin-dependent type 2 diabetes patients.
The company has entered strategic collaborations to broaden its product ecosystem: a license agreement with Xeris Pharmaceuticals to co-develop a pump-compatible glucagon formulation, and a development/commercialization pact with Abbott Diabetes Care to advance an automated insulin-delivery system. Beta Bionics was incorporated in 2015 and is headquartered in Irvine, California.
From a market-size perspective, the global insulin-pump market is projected to grow at a CAGR of roughly 7 % through 2030, driven by rising diabetes prevalence (≈ 10 % of the U.S. adult population) and increasing reimbursement pressure for closed-loop solutions. As of the most recent filing (Q2 2024), BBNX reported a cash runway of about $70 million, a net loss of $45 million for the twelve-month period, and zero product revenue, underscoring the high-risk, high-reward nature of its commercialization timeline.
Given the company’s early-stage revenue profile, investors should monitor key milestones such as FDA clearance of the Patch Pump, the commercial launch of the bihormonal iLet, and the execution of its Abbott partnership, as these events will materially affect cash burn and valuation multiples.
For a deeper dive into BBNX’s valuation metrics and peer comparison, the ValueRay platform offers a concise, data-driven snapshot.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-77.8m TTM) > 0 and > 6% of Revenue (6% = 5.31m TTM) |
| FCFTA -0.18 (>2.0%) and ΔFCFTA 26.52pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 276.2% (prev 122.0%; Δ 154.3pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.17 (>3.0%) and CFO -56.6m > Net Income -77.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 10.64 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (43.6m) change vs 12m ago 596.6% (target <= -2.0% for YES) |
| Gross Margin 54.51% (prev 55.17%; Δ -0.66pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 41.49% (prev 54.71%; Δ -13.22pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -33.9k (EBITDA TTM -65.4m / Interest Expense TTM 2000 ) >= 6 (WARN >= 3) |
Altman Z'' -11.39
| (A) 0.74 = (Total Current Assets 270.0m - Total Current Liabilities 25.4m) / Total Assets 330.0m |
| (B) -1.08 = Retained Earnings (Balance) -356.5m / Total Assets 330.0m |
| warn (B) unusual magnitude: -1.08 — check mapping/units |
| (C) -0.32 = EBIT TTM -67.8m / Avg Total Assets 213.5m |
| (D) -10.09 = Book Value of Equity -356.1m / Total Liabilities 35.3m |
| Total Rating: -11.39 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 35.25
| 1. Piotroski 0.0pt |
| 2. FCF Yield -5.72% |
| 3. FCF Margin -68.34% |
| 4. Debt/Equity 0.03 |
| 5. Debt/Ebitda 0.47 |
| 6. ROIC - WACC (= -44.93)% |
| 7. RoE -31.57% |
| 8. Rev. Trend 82.96% |
| 9. EPS Trend 91.22% |
What is the price of BBNX shares?
Over the past week, the price has changed by +6.63%, over one month by +0.92%, over three months by +38.38% and over the past year by +34.11%.
Is BBNX a buy, sell or hold?
- Strong Buy: 4
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BBNX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 32.3 | 1.9% |
| Analysts Target Price | 32.3 | 1.9% |
| ValueRay Target Price | 34 | 7.4% |
BBNX Fundamental Data Overview December 20, 2025
P/S = 14.4446
P/B = 4.3388
Beta = None
Revenue TTM = 88.6m USD
EBIT TTM = -67.8m USD
EBITDA TTM = -65.4m USD
Long Term Debt = 7.69m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.98m USD (from shortTermDebt, last quarter)
Debt = 7.69m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -30.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.06b USD (1.28b + Debt 7.69m - CCE 228.7m)
Interest Coverage Ratio = -33.9k (Ebit TTM -67.8m / Interest Expense TTM 2000 )
FCF Yield = -5.72% (FCF TTM -60.5m / Enterprise Value 1.06b)
FCF Margin = -68.34% (FCF TTM -60.5m / Revenue TTM 88.6m)
Net Margin = -87.89% (Net Income TTM -77.8m / Revenue TTM 88.6m)
Gross Margin = 54.51% ((Revenue TTM 88.6m - Cost of Revenue TTM 40.3m) / Revenue TTM)
Gross Margin QoQ = 55.48% (prev 53.80%)
Tobins Q-Ratio = 3.21 (Enterprise Value 1.06b / Total Assets 330.0m)
Interest Expense / Debt = 0.03% (Interest Expense 2000 / Debt 7.69m)
Taxrate = 21.0% (US default 21%)
NOPAT = -53.6m (EBIT -67.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.64 (Total Current Assets 270.0m / Total Current Liabilities 25.4m)
Debt / Equity = 0.03 (Debt 7.69m / totalStockholderEquity, last quarter 294.8m)
Debt / EBITDA = 0.47 (negative EBITDA) (Net Debt -30.8m / EBITDA -65.4m)
Debt / FCF = 0.51 (negative FCF - burning cash) (Net Debt -30.8m / FCF TTM -60.5m)
Total Stockholder Equity = 246.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -23.59% (Net Income -77.8m / Total Assets 330.0m)
RoE = -31.57% (Net Income TTM -77.8m / Total Stockholder Equity 246.5m)
RoCE = -26.68% (EBIT -67.8m / Capital Employed (Equity 246.5m + L.T.Debt 7.69m))
RoIC = -32.24% (negative operating profit) (NOPAT -53.6m / Invested Capital 166.2m)
WACC = 12.68% (E(1.28b)/V(1.29b) * Re(12.76%) + D(7.69m)/V(1.29b) * Rd(0.03%) * (1-Tc(0.21)))
Discount Rate = 12.76% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 169.1%
Fair Price DCF = unknown (Cash Flow -60.5m)
EPS Correlation: 91.22 | EPS CAGR: 13.1k% | SUE: N/A | # QB: 0
Revenue Correlation: 82.96 | Revenue CAGR: 196.8% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.43 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=6
EPS next Year (2026-12-31): EPS=-1.66 | Chg30d=+0.000 | Revisions Net=+2 | Growth EPS=+13.7% | Growth Revenue=+36.1%
Additional Sources for BBNX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle